Drawing from insights gained through the network pharmacology and molecular docking analysis, a compelling hypothesis emerges: SKP’s mitigation of ferroptosis in diabetic nephropathy primarily hinges on the inhibition of HIF-1α/HO-1 signaling pathway. This evidence concerns the gene HIF1A and diabetic kidney disease.